	US 11,992,496 B1
	Oral testosterone therapy
Nachiappan Chidambaram, Salt Lake City, UT (US); Satish K. Nachaegari, Salt Lake City, UT (US); Mahesh V. Patel, Salt Lake City, UT (US); and Kilyoung Kim, Salt Lake City, UT (US)
Filed by Lipocine Inc., Salt Lake City, UT (US)
Filed on May 2, 2023, as Appl. No. 18/310,784.
Application 18/310,784 is a continuation of application No. 17/132,167, filed on Dec. 23, 2020, granted, now 11,672,807.
Application 17/132,167 is a continuation of application No. 16/727,737, filed on Dec. 26, 2019, granted, now 10,881,670, issued on Jan. 5, 2021.
Application 16/727,737 is a continuation of application No. 15/828,320, filed on Nov. 30, 2017, abandoned.
Claims priority of provisional application 62/428,317, filed on Nov. 30, 2016.
Claims priority of provisional application 62/428,167, filed on Nov. 30, 2016.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/568 (2006.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61P 5/24 (2006.01)

CPC A61K 31/568 (2013.01) [A61K 9/0053 (2013.01); A61K 9/48 (2013.01); A61P 5/24 (2018.01); A61K 9/4858 (2013.01)]

30 Claims

1. A method of treating a subject having a condition associated with at least one of fatigue, a reduction in muscle size, and a reduction in muscle strength, said method comprising orally administering a pharmaceutical composition comprising a therapeutically effective amount of a non-undecanoate testosterone ester in an untitrated dose administration regimen with food.